Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aminopeptidase P (APP) is a metalloenzyme that specifically cleaves the N-terminal amino acid from peptides and proteins where the second residue is proline. It exists in both membrane-bound and soluble forms and plays a role in the degradation of bioactive peptides like bradykinin. APP is implicated in various physiological processes and diseases, including cancer, inflammation, and cardiovascular regulation, making it a potential therapeutic target and biomarker.
Inhibiting the enzymatic activity of Aminopeptidase P, leading to altered levels of proline-containing peptides such as bradykinin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aminopeptidase P (None).